1
Experience of Using Lipano in Children With Fatty Acid Oxidation Disorders
Condition(s):Fatty Acid Oxidation DisorderLast Updated:May 22, 2020Completed
Fatty Acid Oxidation Disorder: 57 Clinical Trials, Page 1 of 6
Hide Studies Not Open or Pending
2
A Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders
Condition(s):Fatty Acid Oxidation DisordersLast Updated:August 26, 2019Recruiting
3
Fatty Acid Oxidation Disorders & Body Weight Regulation Grant
Condition(s):Trifunctional Protein DeficiencyLast Updated:April 22, 2013Completed
4
Clinical Outcome of Triheptanoin Treatment in Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Treated Under Expanded Access Program
Condition(s):Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)Last Updated:July 10, 2020Completed
5
High Protein Diet in Patients With Long-chain Fatty Acid Oxidation Disorders
Condition(s):Very Long-chain Acyl-CoA Dehydrogenase Deficiency; Trifunctional Protein Deficiency; Carnitine Palmitoyltransferase 2 Deficiency; Long-chain 3-hydroxyacyl-CoA Dehydrogenase DeficiencyLast Updated:April 29, 2020Completed
6
Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder
Condition(s):Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency; Carnitine Palmitoyltransferase 2 (CPT2) Deficiency; Mitochondrial Trifunctional Protein (TFP) Deficiency; Long-chain 3 hydroxyacylCoA Dehydrogenase (LCHAD) DeficiencyLast Updated:March 23, 2017Completed
7
Resveratrol Supplementation in Patients With Mitochondrial Myopathies and Skeletal Muscle Fatty Acid Oxidation Disorders
Condition(s):Mitochondrial Myopathies; Fatty Acid Oxidation DefectsLast Updated:November 27, 2019Completed
8
An Open-label Phase 2 Study of UX007 (Triheptanoin) in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
Condition(s):Long-chain Fatty Acid Oxidation Disorders (LC-FAOD); Carnitine Palmitoyltransferase (CPT II) Deficiency; Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency; Longchain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency; Trifunctional Protein (TFP) DeficiencyLast Updated:October 25, 2019Completed
9
Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies.
Condition(s):Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency; Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency; Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency; Trifunctional Protein (TFP) Deficiency; Carnitine-acylcarnitine Translocase (CACT) DeficiencyLast Updated:June 4, 2020Enrolling by invitation
10
Expanded Access to Triheptanoin
Condition(s):Long-chain Fatty Acid Oxidation Disorders (LC-FAOD); Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)Last Updated:May 20, 2020Available